| Literature DB >> 29765304 |
Negah Rahmati1, Freek E Hoebeek1,2, Saša Peter1, Chris I De Zeeuw1,3.
Abstract
The intraneuronal ionic composition is an important determinant of brain functioning. There is growing evidence that aberrant homeostasis of the intracellular concentration of Cl- ([Cl-]i) evokes, in addition to that of Na+ and Ca2+, robust impairments of neuronal excitability and neurotransmission and thereby neurological conditions. More specifically, understanding the mechanisms underlying regulation of [Cl-]i is crucial for deciphering the variability in GABAergic and glycinergic signaling of neurons, in both health and disease. The homeostatic level of [Cl-]i is determined by various regulatory mechanisms, including those mediated by plasma membrane Cl- channels and transporters. This review focuses on the latest advances in identification, regulation and characterization of Cl- channels and transporters that modulate neuronal excitability and cell volume. By putting special emphasis on neurons of the olivocerebellar system, we establish that Cl- channels and transporters play an indispensable role in determining their [Cl-]i and thereby their function in sensorimotor coordination.Entities:
Keywords: GABAergic inhibition; cerebellar motor learning; chloride homeostasis; chloride transporters and channels; olivocerebellar system
Year: 2018 PMID: 29765304 PMCID: PMC5938380 DOI: 10.3389/fncel.2018.00101
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Figure 1GABAergic signaling in olivo-cerebellar circuit. (A) Schematic representation of a sagittal section of the mouse olivo-cerebellar system (left). Inferior olivary neurons (shown in blue) project to the cerebellar cortex (gray) and excite Purkinje cells (brown), as well as the deeply located cerebellar nuclei (CN) neurons (pink). A particular subset of CN neurons projects back to the inferior olive (IO), forming the olivo-cortico-nuclear loop. The right panel demonstrates the anatomical circuit of the cerebellar cortical neurons and their connectivity with CN and the IO. ML, molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer; PC, Purkinje cell; GrC, granule cell; SC, stellate cell; BC, basket cell; GoC, Golgi cell; PF, parallel fiber; CF, climbing fiber; MF, mossy fiber; CN, cerebellar nuclei; IO, inferior olive. (B) The level of intracellular chloride concentration ([Cl−]i) dictates the polarity of the current through GABAA receptors (GABAARs). If [Cl−]i is low, the reversal potential of Cl− (ECl) becomes negative compared to the resting membrane potential (RMP). In this condition GABAARs mediate an inward Cl− current that results in hyperpolarization of the cell membrane (a). In contrast, high [Cl−]i results in a positive shift of ECl and leads to an outward Cl− current through GABAAR and depolarization of the cell membrane that potentially induces action potential firing (c). In conditions where ECl shifts to values similar to RMP, there will be no net Cl− current through GABAARs (b).
ClC family of voltage-gated Cl− channels.
| ClC-1 | Skeletal muscle, smooth muscle, heart, brain? | Stabilizing membrane potential in muscle | Myotonia congenita | Myotonia congenita, altered neuronal excitability | Inhibitors: Zn2+ and Cd2+, 9-AC, DPC, and niflumic acid | Lorenzetto et al., |
| ClC-2 | Broad (brain, heart, muscle, kidney,…) | Transepithelial transport, cell volume control, neuronal excitability | Cardiovascular disease, epilepsy? | Leukoencephalopathy, degeneration of retina and testis, altered neuronal excitability | Inhibitors: Zn2+ and Cd2+, DIDS, SITS | Smith et al., |
| ClC-3 | Broad (brain, heart, muscle, kidney,…) | Vesicular and endosomal acidification | ? | Hippocampal neuronal degeneration, degeneration of retina | Kawasaki et al., | |
| ClC-5 | Kidney, intestine | Endosomal acidification | Dent's disease | Defects in renal endocytosis, proteinuria, hyperphosphaturia | Günther et al., | |
| ClC-6 | Brain | Endosomal acidification | ? | Lysosomal storage disease | Brandt and Jentsch, | |
| ClC-7 | Broad (brain, bone, kidney,…) | Lysosomal Cl− regulation, acidification of osteoclast, resorption lacunae | Osteopetrosis, neuronal ceroid lipofuscinosis, retinal degeneration, lysosomal storage disease | Lysosomal storage disease, retinal degeneration, osteopetrosis | Brandt and Jentsch, | |
| ClC-Kb | Kidney, inner ear | Transepithelial transport, salt reabsorption | Bartter syndrome type III | Salt loss, deafness | Inhibited by phenylbenzofuran carboxylic acids | Kobayashi et al., |
TMEM16 (Anoctamin) family.
| TMEM16A (Ano1) | Epithelial tissue, smooth muscle, interstitial cells of Cajal, dorsal root ganglion neurons | ClCa channel, involved in fluid secretion, muscle contraction, gastrointestinal contractility, pain processing | Tumor growth, cystic fibrosis, asthma | Low blood pressure | Inhibitors: CaCCinh-A01, CaCCinh-B01, Niflumic acid (NFA), and NPPB, agonists: INS37217 | Chen et al., |
| TMEM16B (Ano2) | Brain (hippocampal and thalamocortical neurons, olfactory bulb, inferior olive, Purkinje cells), retina, muscle | ClCa channel, involved in neuronal excitability, olfactory and sensory signal transduction and smooth muscle contraction | ? | Impaired motor behavior, partial reduction of electrical response to odorants, normal olfaction | Inhibitors: CaCCinh-A01, CaCCinh-B01, Niflumic acid (NFA) agonists: INS37217 | Stöhr et al., |
| TMEM16C (Ano3) | Brain (dorsal root ganglion cells), blood vessels, lung | Phospholipid scrambling, KNa channel regulator | Craniocervical dystonia, tremor, asthma | Impaired endoplasmic reticulum-dependent Ca2+ signaling | Charlesworth et al., | |
| TMEM16E (Ano5) | Muscle, bone, sperm | Phospholipid scrambling | Muscular dystrophy, gnathodiaphyseal dysplasia | Katoh, | ||
| TMEM16F (Ano6) | Blood vessels, endosomes, brain? | Phospholipid scrambling, blood coagulation, SCANCa channel, ClCa channel, involved in membrane excitability | Scott syndrome | Lysosomal storage disease | Suzuki et al., | |
| TMEM16J (Ano9) | Epithelial cells, colonic tissue | Phospholipid scrambling | Colorectal carcinoma | Suzuki et al., | ||
| TMEM16K (Ano10) | Epithelial cells, cerebellum? | Intracellular protein involved in intracellular Ca2+ signaling, essential for apoptosis | Autosomal recessive cerebellar ataxia | Vermeer et al., |
Figure 2Diagram of chloride channels and transporters that are expressed in the olivocerebellar neurons. The intracellular Cl− concentration in all neurons, including the neurons of cerebellum and inferior olive, is maintained by activation of various transmembrane anion channels and transporters. These anion transporters/channels also interact with H+ exchangers/channels, such as NHE1 and H+-ATPase, and thereby are involved in intracellular pH regulation. Cell membrane depolarization, through voltage-gated Na+ channels (VGSCs), activates several Cl− channels/transporters, such as SLC26A11 (KBAT), to repolarize the cell by mediating inward Cl− currents. In addition, depolarizations activate voltage-gated Ca2+ channels (VGCCs) and the resulting rise in intracellular Ca2+ levels, which may be aided by internal Ca2+ stores, may lead to activation of Ca2+ sensitive Cl− channels, such as anoctamin-2 (Ano2). Transmembrane movements of Cl− together with cations such as K+ and Na+ also control cell volume through transport of water molecules. Channels and transporters which belong to the same family of proteins are shown with a similar color.
SLC4 family of anion transporters.
| SLC4A1 (AE1) | Erythrocytes, kidney, heart, colon | Cl−/ | Hemolytic anemia, distal renal tubular acidosis | Inhibitor: DIDS | Bruce et al., | |
| SLC4A2 (AE2) | Most epithelial cells | Cl−/ | Osteopetrosis | Inhibitor: DIDS | Gawenis et al., | |
| SLC4A3 (AE3) | Brain, kidney, GI tract, smooth muscle and heart | Cl−/ | Epilepsy, blindness | Lower seizure threshold | Inhibitor: DIDS | Sander et al., |
| SLC4A8 (NDCBE) | Brain, kidney, testes and ovary | Na+–dependent Cl−/ | ? | Inhibitor: DIDS | Chen et al., | |
| SLC4A10 (NCBE) | Brain | pH regulation (acid extrusion) | ? | Higher seizure threshold, volume reduction of brain ventricles | Inhibitor: DIDS | Chen et al., |
SLC26 family of anion transporters.
| SLC26A1 (SAT1) | Kidney, GI tract, liver, lung | Oxalate urolithiasis, nephrocalcinosis, urinary sulfate wasting, hepatotoxicity | Xie et al., | |||
| SLC26A2 (DTDST) | Kidney, GI tract, chondrocytes | Cl−/ | Diastrophic dysplasia | Diastrophic dysplasia | Hästbacka et al., | |
| SLC26A3 (DRA) | GI tract, epididymis, enterocytes | Cl−/ | Congenital chloride diarrhea | Congenital chloride diarrhea | Höglund et al., | |
| SLC26A4 (pendrin) | Kidney, inner ear, thyrocytes, lung | Cl−/ | Pendred syndrome | Deafness, enlargement of the vestibular aqueduct | Reardon and Trembath, | |
| SLC26A5 (prestin) | Cochlear hair cells | Cl−/ | Deafness | Deafness | Liberman et al., | |
| SLC26A6 (PAT1) | GI tract, kidney, cardiac myocytes | Cl−/ | ? | Soleimani, | ||
| SLC26A7 | Brain, kidney, GI tract, lung | Cl−/ | ? | Locomotor impairment, gastric hypochlorhydria, distal renal tubular acidosis | Inhibitor: DIDS | Kim et al., |
| SLC26A8 | Male germ cells, kidney | Cl−/Ox2− exchanger, Cl−/ | ? | Male infertility | Touré et al., | |
| SLC26A9 | Stomach, lung, lower levels in kidney | Cl−/ | ? | Hypertension | Xu et al., | |
| SLC26A11 (KBAT) | Brain, kidney, GI tract | Cl− channel, Cl−/ | ? | Locomotor impairment | Inhibitor: GlyH-101, CFTRinh, DIDS (partial inhibition) | Vincourt et al., |
SLC12 family of cation-chloride cotransporters.
| SLC12A1 (NKCC2) | Kidney, gastrointestinal tract, pancreatic β-cells, induced in hypothalamo- neurohypophyseal system (HNS) by osmotic stress | Na+/K+/Cl− cotransporter involved in salt reabsorption | Bartter's syndrome type I | Sever hypotension, hypokalemia, hypercalcinuria, metabolic alkalosis | Inhibitors: bumetanide (10 μM), furosemide | Rocha and Kokko, |
| SLC12A2 (NKCC1) | Broad | Na+/K+/Cl− cotransporter involved in regulation of [Cl−]i and cell volume, regulation of EGABA in neurons | Dehydration, vomiting, dilated cardiomyopathy, respiratory weakness, pancreatic insufficiency, missense mutation in a group of patients with schizophrenia, seizure-like episodes | Impaired sensory perception, deafness, infertility, hypotension, reduction of saliva production, normal intestinal absorption, enhanced insulin secretion and improved glucose tolerance | Inhibitors: bumetanide (10 μM), furosemide | Cherubini et al., |
| SLC12A3 (NCC) | Kidney, peripheral blood mononuclear cells, colon, spleen, placenta, small intestine, prostate | Na+/Cl− cotransporter involved in salt reabsorption | Gitelman syndrome | Hypotension, hypokalemia, hypercalcinuria, hypomagnesemia | Inhibitor: thiazide | Costanzo, |
| SLC12A4 (KCC1) | Broad | K+/Cl− cotransporter, involved in cell volume regulation | ? | No phenotype is reported | Inhibitor: furosemide | Kanaka et al., |
| SLC12A5 (KCC2) | Brain, pancreatic β-cells, adrenal chromaffin cells, cancer cells | K+/Cl− cotransporter, involved in regulation of [Cl−]i, neuronal excitability and cell volume, modulation of insulin secretion | Epilepsy, tumor invasion/metastasis | Complete KO: death conditional KO: increased [Cl−]i, positive shift of EGABA, neuronal hyperexcitability, impaired motor performance, and motor learning | Inhibitors: bumetanide (100 μM), furosemide, VU0463271, VU 0240551, ML077 activator: CLP257 | Williams et al., |
| SLC12A6 (KCC3) | Broad | K+/Cl− cotransporter, involved in cell volume regulation | Andermann syndrome (ACCPN), epilepsy? | Hypertension, progressive neurodegeneration, reduced seizure threshold, deafness | Inhibitor: furosemide | Pearson et al., |
Ligand-gated chloride channels.
| GABAAR | Nervous system | Inhibitory synaptic transmission in the brain, neuronal excitability and development | Epilepsy, movement disorders, cognitive disorders, autism, anxiety disorders, schizophrenia, sleep disorders, mood disorders | Epilepsy, movement disorders, impaired motor learning and cognition | Agonists: benzodiazepines, barbiturates, zolpidem, muscimol antagonists: bicuculline, picrotoxin, Cu2+ (blocks tonic inhibition) | Kaila, |
| GlyR | Nervous system | Inhibitory synaptic transmission in the central nervous system, neuronal excitability and development | Startle disease, autism | Natural occurring mutation: startle disease | Agonists: Taurine, α-L-alanine, L-serine, low concentration of Zn2+, antagonists: strychnine, high concentration of Zn2+ | Curtis et al., |
| SLC1A4 (EAAT4) | Nervous system | Glutamate/Na+/Cl− transport, involved in neuronal excitability and development | Neurodegenerative disorders, stroke | Down-regulation of EAAT4 leads to PC hyperexcitability | Agonists: TBOA, L-α-aminoadipate, T3MG, Zn2+ (selective blocker of Cl− conductance) | (Fairman et al., |